舒泰神(300204.SZ):換髮藥品生產許可證及營業執照
格隆匯 1 月 12日丨舒泰神(300204.SZ)公佈,公司於近期取得了北京市藥品監督管理局換髮的藥品生產許可證,主要信息如下:
企業名稱:舒泰神(北京)生物製藥股份有限公司;社會信用代碼:911100007423131451;註冊地址:北京市北京經濟技術開發區經海二路36號;法定代表人:周志文;有效期至:2025年12月07日;許可證編號:京20150112;分類碼:Ahs;生產地址和生產範圍:北京市北京經濟技術開發區經海二路36號:片劑、硬膠囊劑、散劑、口服溶液劑、治療用生物製品***
基於上述藥品生產許可證信息,根據《藥品生產監督管理辦法》的要求,公司向北京經濟技術開發區市場監督管理局申請換髮了營業執照。公司於近日完成了工商變更登記手續,取得了北京經濟技術開發區市場監督管理局換髮的《企業法人營業執照》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.